// App-Quantinova.ai

PB2105 : Risk of venous Thromboembolism among Subgroups of Cancer Patients Undergoing Chemotherapy: Post-Hoc Analysis of the AVERT Trial

Researchers

Presenter

  • A.L. Nayak

Principal Investigators

  • A. Zahrai

  • R. Mallick

  • M. Carrier

  • P. Wells

Medical Centers

  • Rheumatology, University of Ottawa Faculty of Medicine, Ottawa, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • Creatinine

Drug/Treatment

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • NCT02048865

Sponsors

  • Canadian Institutes of Health Research and Bristol-Myers-Squibb-Pfizer Alliance

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved